Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 10/20 | 0.80 |
| ▸ | KDR | P35968 | 11/20 | 0.75 |
| ▸ | ABL1 | P00519 | 3/20 | 0.75 |
| ▸ | RET | P07949 | 3/20 | 0.75 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.75 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.75 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.75 |
| ▸ | PLK4 | O00444 | 2/20 | 0.75 |
| ▸ | AURKA | O14965 | 2/20 | 0.75 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.75 |
| ▸ | LCK | P06239 | 2/20 | 0.75 |
| ▸ | FYN | P06241 | 2/20 | 0.75 |
| ▸ | LYN | P07948 | 2/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.75 |
| ▸ | AXL | P30530 | 2/20 | 0.75 |
| ▸ | FRK | P42685 | 2/20 | 0.75 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.75 |
| ▸ | BLK | P51451 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19878582 | 0.93 | RAF1 (0.69) | RAF1KDRABL1RETEPHA2 | |
| SCHEMBL21124504 | 0.93 | RAF1 (0.69) | RAF1KDRABL1RETEPHA2 | |
| SCHEMBL21084300 | 0.93 | RAF1 (0.69) | RAF1KDRABL1RETEPHA2 | |
| SCHEMBL30104231 | 0.93 | RAF1 (0.69) | RAF1KDRABL1RETEPHA2 | |
| SCHEMBL21124523 | 0.91 | RAF1 (0.81) | RAF1KDRABL1RETEPHA2 | |
| SCHEMBL1660403 | 0.91 | BRAF (0.68) | RAF1KDRABL1RETEPHA2 | |
| SCHEMBL21125213 | 0.91 | RAF1 (0.67) | RAF1KDRABL1RETEPHA2 | |
| SCHEMBL19888751 | 0.91 | RAF1 (0.67) | RAF1KDRABL1RETEPHA2 | |
| SCHEMBL5569095 | 0.91 | RAF1 (0.80) | RAF1KDRABL1RETEPHA2 | |
| SCHEMBL21125214 | 0.90 | RAF1 (0.66) | RAF1KDRABL1RETEPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500257-B1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-07-02 | — | — | EP | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | Ferro Therapeutics, Inc. | 2020-05-07 | — | — | US | disclosed |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3500257-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | Icahn School of Medicine at Mount Sinai (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2011046991-A2 | CERTAIN SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | RAF1 16/4885KDR 706/4885ABL1 38/4885 |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | RAF1 16/4885KDR 706/4885ABL1 38/4885 |
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | AIFM2, GPX4, DDIT3 | RAF1 1212/4885KDR 4064/4885ABL1 1448/4885 |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | RAF1 16/4885KDR 706/4885ABL1 38/4885 |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | RAF1 16/4885KDR 706/4885ABL1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.